A Phase 1 Study to Assess Pharmacokinetics of Metadoxine (MG01CI) 1400 mg, Administered to Healthy Volunteers

• Status: Completed
• Trial end date: 2013-10-01
• Target enrollment: 0
• Participant gender: All

Summary

objective: To assess the safety, tolerability and pharmacokinetics of metadoxine, administered as repeated oral doses of MG01CI tablets (2 X 700 mg metadoxine per administration), to healthy adult subjects.

This is a single center, open-label, repeated-dose study in healthy male and female volunteers. Subjects will undergo screening within 21 days prior to the first dosing to assess their eligibility to participate in the study.

All subjects will receive 1400 mg metadoxine as two MG01CI oral extended-release tablets, administered once daily for five consecutive days.

Blood samples for metadoxine (which consists of two components: pyrrolidone-5-carboxylate and pyridoxine that can be identified in plasma concentration assays) will be drawn at designated time points, as described in the pharmacokinetic (PK) evaluation section. The subjects will remain confined to the unit for 6 days after first dosing.

A study termination visit will take place 10-12 days after the last dosing day. The subjects will be monitored for safety, and AEs (Adverse events) will be recorded throughout the study.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Alcobra Ltd.
• Treatments: Metadoxine; Pyridoxine

Criteria

Inclusion Criteria:

1. Healthy men and women between 18 and 45 years (inclusive) of age.

2. Subjects who provide written informed consent to participate in the study.

3. Body Mass Index (BMI) 19 to 29 kg/m2 (inclusive).

4. Non-smoking and no use of any tobacco or nicotine products (by declaration) for a period of at least 6 months prior to screening visit and a negative urine cotinine test which rules out active smoking at screening visit.

5. Subjects in general good health in the opinion of the investigator as determined by medical history, vital signs and a physical examination.

6. Blood pressure and heart rate within normal limits (blood pressure: systolic 90-140 mmHg; diastolic 50-90 mmHg, heart rate 50-100 beats per minute (bpm).

7. Female subjects must have a negative serum pregnancy test at screening and be willing and able to use a medically acceptable method of birth control or declare that they are abstaining from sexual intercourse, from the screening visit through the study termination visit or be surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) or post-menopausal. Postmenopausal women are defined as women with menstruation cessation for 12 consecutive months prior to signing of the informed consent form.

8. Electrocardiogram (ECG) with no clinically significant Investigator assessment discretion in cases of borderline results is allowed.

9. Negative HIV, Hepatitis B and Hepatitis C serology tests at screening.

10. No clinically significant abnormalities in hematology, blood chemistry, or urinalysis lab tests at screening.

11. No known history of alcohol or drug abuse. Negative urinary drugs of abuse screen determined within 21 days of the start of the study (Screening and check-in visit).

12. Subjects must be able to understand the requirements of the study and must be willing to comply with the requirements of the study.

Exclusion Criteria:

1. Known history of any significant medical disorder, which in the investigator's judgment contraindicates administration of the study medications.

2. Any clinically significant abnormality upon physical examination or in the clinical laboratory tests at screening visit.

3. Use of any prescription or over-the-counter (OTC) medications, including vitamins and herbal or dietary supplements within 14 days prior to first dosing. Paracetamol for symptomatic relief of pain is allowed until 24 hours prior to the first study drug administration.

4. Drug or alcohol abuse.

5. Known hypersensitivity and/or allergy to any drugs.

6. Any acute illness (e.g. acute infection) within 48 hours prior to the first study drug administration, which is considered of significance by the investigator.

7. Participation in another clinical trial with drugs received within 3 months prior to dosing (calculated from the previous study's last dosing date).

8. Subjects who donated blood in the three months or received blood or plasma derivatives in the six months preceding study drug administration.

9. Subjects with an inability to communicate well with the investigators and CRC staff (i.e., language problem, poor mental development or impaired cerebral function).

10. Inability to fast or consume the food provided in the study (including any known food allergies or food restrictions).

11. Pregnant or currently lactating women.

12. Subjects who are non-cooperative or unwilling to sign consent form